MedTrace Logo

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

NCT04174196 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-12-02

No results posted yet for this study

Summary

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

Conditions

Interventions

DRUG

CC-486

Participants will be treated with CC-486 and lenalidomide for 6 cycles

DRUG

Lenalidomide

Participants will be treated with CC-486 and lenalidomide for 6 cycles

RADIATION

Radiation Therapy

Radiation therapy will be initiated to the plasmacytoma after cycle 2

Sponsors & Collaborators

Principal Investigators

  • Urvi Shah, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2026-11-19
Completion
2026-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04174196 on ClinicalTrials.gov